🔗 Share this article

While the United States proceeds with sweeping changes to its vaccine schedules, a particular individual has emerged in a surprising turn: Tracy Beth Høeg, a Danish American sports medicine doctor and public health researcher who initially gained attention by expressing skepticism about Covid shots throughout the global health crisis and has focused upon potential fatalities after Covid immunization in her short tenure at the Food and Drug Administration.

Scheduled Shifts to Childhood Vaccine Schedule

Health officials had intended to announce radical revisions to the pediatric vaccination calendar in December, bringing the US with Denmark’s immunization schedule, it is understood – a substantial departure that would put the US at odds with many the international standard with insufficient data for benefit. The announcement has been delayed until the coming year.

In place of Vinay Prasad, Høeg is listed to address the audience at the meeting. She was newly appointed acting director of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth person to head the division this calendar year.

Consolidating Power at the Agency

This interim role could signify a tighter collaboration between the drug and biologics divisions as Dr. Høeg and Dr. Prasad consolidate power at the regulatory agency – and it points to a increased emphasis upon rolling back long-standing immunizations at the FDA.

Dr. Høeg has often pushed for discontinuing specific childhood vaccine recommendations in the US so as to align more like Denmark's approach, a country with comprehensive healthcare and a number of inhabitants roughly the size of the state of Wisconsin.

In her initial public appearances, she has persisted in emphasizing on vaccination policy – traditionally the domain of Dr. Prasad, head of the FDA’s CBER – instead of drug regulation.

Doubts Over Background

Høeg has no apparent experience in pharmaceutical research, approval processes or management, which has been customary for former leaders of the biologics center. She has served at the FDA as a senior adviser to the FDA chief and CBER since earlier this year.

“She appears not to have any of the qualifications” for overseeing the CDER, stated Jonathan Howard. “She’s never run a randomized controlled trial. She has no expertise in leading a major agency. She is not an expert in pharmaceutical oversight.”

Past directors of the center would “be deeply familiar with regulatory frameworks and the research of drug development”, noted Janet Woodcock. “Clearly, she doesn’t have the kind of background that prior appointees who led CBER have had.”

This division has an immense workload at the FDA, the former commissioner stated.

“The public just pays attention on the novel medication approvals, but the generic drug division authorizes a multitude of generic medications. There’s a biosimilars program, OTC medication office and more, and every single one must be supervised,” Woodcock noted. “The area you neglect, that is precisely what that I always told people is going to bite you.”

Additionally, a significant leadership aspect to the role, which manages over 5,000 employees. “It’s a huge leadership role, if you perform it correctly,” Woodcock said.

Response and Disputed Initiatives

When asked about inquiries about Dr. Høeg's fitness for the role and whether this selection indicates greater collaboration among agency officials on immunizations, a press secretary said that the “concerns rely on flawed premises”.

“This background is consistent with the functions of her role,” the representative stated, citing the period Høeg spent advising the FDA commissioner on “pharmaceutical safety and approval science, including predictive safety algorithms and vaccine surveillance”.

As the temporary head, Dr. Høeg assumes responsibility for the agency head's recently launched priority voucher program, a contentious expedited drug-approval program that reportedly worried her predecessors. “How are these drugs being picked for this voucher program? Who is making the decisions?” Howard asked. “There is a lot of lack of transparency happening at the agency right now.”

In general, he said, “the agency seems to be moving towards more relaxed rules of pharmaceuticals, except for immunizations.”

Public Track Record on Vaccines

Regarding immunizations, Høeg has a clearer, if concerning, history, some experts have noted. She authored a research paper using unverified crowd-sourced reports to estimate the incidence of myocarditis after Covid vaccination. She consulted for the Florida surgeon general Dr. Joseph Ladapo, who was said to have altered data to indicate COVID-19 vaccinations are pose a greater threat than they are.

Among her “desired changes” for the incoming government featured changing rules for novel immunizations and halting “unnecessary” immunizations, she said following the vote on a podcast. At the agency, Høeg has reportedly proposed barring young men from obtaining Covid vaccinations.

“She is an all-around ideologue who begins with her conclusions and works backwards to accommodate the evidence in a very deceptive, dishonest way,” Howard said.

Taking Control and a “Revenge Tour”

Dr. Høeg joined other contrarians, {like|